Sirtris Pharmaceuticals, Inc. - Current report filing (8-K)
February 25 2008 - 4:07PM
Edgar (US Regulatory)
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON,
D.C. 20549
FORM 8-K
CURRENT REPORT
PURSUANT TO SECTION 13 OR 15(D) OF THE
THE SECURITIES EXCHANGE ACT OF 1934
Date
of report (Date of earliest event reported):
February 25,
2008
SIRTRIS PHARMACEUTICALS, INC.
(Exact
name of registrant as specified in its charter)
Delaware
|
|
001-33465
|
|
20-1410189
|
(State or other jurisdiction of
of incorporation or organization)
|
|
(Commission
File Number)
|
|
(I.R.S. Employer
Identification No.)
|
200 Technology Square, Cambridge, Massachusetts 02139
(Address
of Principal Executive Offices) (Zip Code)
Registrants
telephone number, including area code:
(617) 252-6920
790 Memorial Drive
Cambridge, MA 02139
(Former name or former address, if changed since
last report.)
|
|
Check the appropriate
box below if the Form 8-K filing is intended to simultaneously satisfy
the filing obligation of the
|
registrant under any of
the following provisions (
see
General
Instruction A.2. below):
|
o
|
|
Written communications
pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
|
o
|
|
Soliciting material
pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
|
o
|
|
Pre-commencement
communications pursuant to Rule 14d-2(b) under the Exchange Act (17
CFR 240.14d-2(b))
|
o
|
|
Pre-commencement
communications pursuant to Rule 13e-4(c) under the Exchange Act (17
CFR 240.13e-4(c))
|
Item 2.02
Results
of Operations and Financial Condition.
On
February 25, 2008, Sirtris Pharmaceuticals, Inc. issued a press
release relating to its results of operations and financial conditions for the
fiscal year ended December 31, 2007. A copy of the press release is
furnished as Exhibit 99.1 to this form 8-K.
Item 9.01
Financial
Statements and Exhibits.
(d) Exhibits
99.1
Press Release issued by Sirtris Pharmaceuticals, Inc. on
February 25, 2008.
2
Signature
Pursuant
to the requirements of the Securities Exchange Act of 1934, the registrant has
duly caused this report to be signed on its behalf by the undersigned hereunto
duly authorized.
|
|
SIRTRIS PHARMACEUTICALS, INC.
|
|
|
|
|
Date:
February 25, 2008
|
|
By:
|
/s/ CHRISTOPH WESTPHAL
|
|
|
Name:
|
Christoph
Westphal
|
|
|
Title:
|
President
and Chief Executive Officer
|
3
Index to
Exhibits
Exhibit No.
|
|
Description
|
99.1
|
|
Press
Release issued by Sirtris Pharmaceuticals, Inc. on February 25,
2008.
|
4
Sierra Natl BK Tehachapi Calif (MM) (NASDAQ:SIRT)
Historical Stock Chart
From Jun 2024 to Jul 2024
Sierra Natl BK Tehachapi Calif (MM) (NASDAQ:SIRT)
Historical Stock Chart
From Jul 2023 to Jul 2024